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Copyright © 2009 JCBN Summary Although anti-cancer effects of cyclooxygenase 2 (COX2) inhibitors have been
reported, most studies focused on the direct effects of COX2 inhibiters on colon cancer cells.
On the other hand, several types of cancers express Fas ligand (FasL) and/or TRAIL and
mediate apoptosis of T cells in vitro. The “counter-attack” machinery may account for the
mechanisms by which tumors evade host immune surveillance. In this study we determined if
COX2 inhibitor could modulate effector molecules of cell death on colon cancer cells changing
their effects on cytotoxic T lymphocytes. Colon adenocarcinoma cells, HCA7 and HCT116, the
former COX2-positive and the latter COX2-negative, were pre-incubated with/without a
COX2 inhibitor, NS398. Subsequently, the cells were co-cultured with Jurkat T cell leukemia
cells and damage to Jurkat cells was determined. Treatment with NS398 resulted in reduction
of expression of FasL and TRAIL in HCA7 cells, whereas NS398 did not affect the expression
of FasL and TRAIL in HCT116 cells. The number of viable Jurkat cells was diminished when
cells were co-cultured with naive, non-pretreated HCA7 or HCA116 cells. Preincubation of
HCA7 cells with NS398 before co-culture blunted the HCA7 cell-induced cell toxicity on
Jurkat cells. In contrast, pretreatment with NS398 failed to inhibit the HCT116-induced
Jurkat cell killing. Our results suggest that COX2 regulates the expression of FasL and
TRAIL on COX2-positive colon cancer cells thereby evoking a counter-attack against cyto-
toxic T cells, which may lead to compromised host immune responses.
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Introduction
Cyclooxygenase (COX), a key enzyme required for the
synthesis of prostaglandins, exists in two different isoforms,
COX1 and COX2. Although COX2 is not detectable in
most tissues, it is known that its expression is regulated
by mitogenic stimuli and tumor promoters [1–4]. COX2 is
overexpressed in about 40% of adenomatous polyps and
85% of colorectal cancer [5]. The ratio of COX2 positive
polyps increased in a size-dependent manner [6]. Moreover
COX2 overexpression in colon cancer was associated with
tumor size, stage and the status for lymph node metastasis
[7].
Several studies have shown that inhibitors for COX2
reduce the incidence and development of colorectal cancer.
Celecoxib, a COX2 selective inhibitor, reduced colon
polyps in familial adenomatous polyposis (FAP) patients
in a 6-month, randomized, controlled clinical trial [8, 9].
Further, numerous experiment in animal studies demon-
strated a significant efficacy of selective COX2 inhibitors
for the prevention of colorectal tumors [10–14]. The preciseQ. Wang et al.
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mechanisms by which a selective COX2 inhibitor prevents
growth of polyps or the progression of existing polyps are
not fully understood. Nevertheless, there are some reports
suggesting that several anti-tumor mechanisms are involved,
including the ability to induce apoptosis in colon cancer
cells [15], the capacity to inhibit angiogenesis and the
possibility to prevent migration and/or invasion of colon
cancer cells [16–19].
It is often observed that tumors are infiltrated with
lymphocytes. The tumor infiltrating lymphocytes (TILs)
have been reported to correlate with prognosis of cancer-
bearing patients [20]. Moreover, the presence of TILs
appears to be associated with less aggressive behavior of
malignat neoplasms [21]. This might suggest that tumor
cells are vulnerable to attack by immune effector cells such
as lymphokine-activated killer cells, cytotoxic T lympho-
cytes (CTLs) and macrophages [21,  22]. However, the
function of tumor-infiltrating lymphocytes, circulating T
cell was suggested to be impaired [23, 24].
Immuno-suppression occurs in tissues where PGE2 is
high. Moreover, it has been demonstrated that the impaired
functions of immune cells were restored with treatment
with COX2 selective inhibitors [25]. These studies suggest a
possibility that PGE2 itself or induction of COX2 protein
could suppress lymphocyte proliferation and/or cytotoxicity
[26–28].
On the other hand, cancer cells occasionally express Fas
ligand (FasL) or TRAIL to “counterattack” infiltrating
cytotoxic T and/or natural killer cells. Several types of
human cancers express FasL and/or TRAIL and mediate
apoptosis of T cells in vitro [29–32].
These observations collectively led us to hypothesize that
induction of COX2 protein in colonic tumors could modu-
late functions and viability of tumor-infiltrating CTLs. In
this study we report that COX2 potentiates killing functions
of the COX2-positive colonic cancer cells and this event
is mediated by two apoptosis-related molecular systems,
FasL/Fas and TRAIL/DR4.
Materials and Methods
Cell culture and treatments
A human colonic adenocarcinoma cell line HCT116, the
Jurkat human T cell leukemia cell line and U937 human
macrophage cell line were obtained from American Type
Culture Collection (Rockville, MD). HCA7, another human
colonic adenocarcinoma cells were a generous gift from
Dr. Raymond N Dubios (Vanderbilt University Department
of Gastroenterology). HCT116 and HCA7 cells were grown
in Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FCS),
100 U/ml ampicillin and 100 mg/ml streptomycine (Life
Technologies, Rockville, MD). Jurkat and U937 cells were
grown in RPMI 1640 medium with same concentrations of
FCS and antibiotics. Cells were cultured at 37°C in the
atmosphere of 95% air/5% CO2.
WST assay
HCA7 cells were suspended with DMEM culture medium
at the concentration of 50,000 cells/ml. 100 µl of the cell
suspension was inoculated onto the each well of a 96-well
plate then pre-incubated at 37°C for 24 h. Various concentra-
tions of NS398 (0, 1, 10, 100 µM) were added to each
well. Moreover those cells were incubated 48 h. 10 µl of
Cell Counting Kit-8 solutions (Kumamoto, Japan) were
administrated to the each well, and incubated for 1 h. Cell
viability in each well was determined by measuring the
absorbance of 450 nm wave length.
Co-culture of colon cancer cells and Jurkat cells
HCA7 and HCT116 cells were inoculated onto 96 well
culture plate at 1.8 × 104 and 1 × 104/well, respectively.
The cell lines were grown in DMEM containing FCS plus
antibiotics. Fifty-two hours after the inoculation, both cell
lines became sub-confluent, and were washed with PBS
twice. Subsequently, cells were incubated with a selective
COX2 inhibitor NS398 (1 or 10 µM) (Sigma, St Louis,
MO), or with an anti-FasL neutralizing antibody (Santa
Cruz, CA) (83.3 nM), an anti-TRAIL neutralizing antibody
(Santa Cruz) (83.3 nM), or both for another 18 h.
Jurkat cells were inoculated onto the well (3 cm in
diameter) at 8 × 105/well followed by culture for 30 h. Then,
3H-methyl-thymidine (3HMT, 5 mCi/ml) was added to the
culture media and incubation continued for additional 18 h.
The  3HMT-labeled Jurkat cells were detached from the
plate by tripsinization, washed three times with RPMI 1640
containing 5% fetal calf serum. The 3HMT-labeled Jurkat
cells thus prepared were used for co-culture for 18 h with
either HCA7 or HCT116 colon cancer cells (2 × 104 cells/
well) that had been treated with NS398, anti-FasL and/or
anti-TRAIL antibodies. The ratio of the effector (HCA7 or
HCT116) cells to the target (Jurkat) cells (T/E ratio) was 10.
Cell cytotoxicity assay
Following co-culture of 3HMT-labeled Jurkat and colon
cancer cells for 18 h, Jurkat cells were harvested by trapping
onto a grass fiber membrane. The radioactivity remaining in
Jurkat cells was measured by a scintillation counter.
Protein extraction
HCA7, HCT116, Jurkat or U937 cells were incubated
in the presence or absence of NS398 (10 µM) for18 h.
Subsequently, whole cells were collected, suspended in the
lysis buffer (150 mM NaCl, 1% Triton X-100, 0.5% Na
deoxycholate, 0.1% SDS with protease inhibitors) and
vortexed for 5 min on ice. After 30 min of incubation, theCOX2 Modulates Killing of CTL by Colon Cancer Cells
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suspensions were centrifuged at 15,000 rpm for 15 min. The
cell lysates were stored at −80°C until used.
Western blotting
The total concentration of cytoplasmic proteins was
determined by the Bradford assay (Bio-Rad Laboratories,
Hercules, CA). Thirty µg of cytoplasmic protein from each
sample was diluted in SDS-PAGE loading buffer, boiled
for 5 min and loaded onto 10% or 12% SDS-PAGE gel.
The proteins were transferred to the Hybond-P positively
charged nylon membrane (Amersham Life Science, Arlington
Heights, IL) using a Hofer semiphor (Pharmacia Biotech
Piscataway, NJ) semi-dry blotting device. After non-specific
binding was blocked with 3% Blotto (3% dry milk, 150 mM
NaCl, 20 mM Tris-HCl pH 7.5, and 0.05% Triton X100)
overnight at room temperature, the membranes were incu-
bated with primary antibodies against COX2, FasL, TRAIL,
DR4 or Fas (Santa Cruz CA) at the concentration of 1:200.
Excess primary antibodies were washed and removed, and
then membranes were incubated with a horseradish per-
oxidase-conjugated secondary IgG antibody at a dilution of
1:2,000 in 3% Blotto solution for 1 h. Subsequently, the
membranes were washed 3 times each with TBST (150 mM
NaCl, 20 mM Tris-HCl pH 7.5, 0.05% Triton X100). The
membranes were then developed for 2 min with ECL regents
(Amersham Life Science).
Immunofluorescence analysis
HCA7 and HCT116 cells were plated on 15 mm dishes
and grown for 48 h. Cells were fixed with 1% paraformalde-
hyde for 10 min, and incubated 1 h with primary antibodies
aganist FasL or TRAIL, diluted 1:500, in the presence of
10% normal goat serum. followed by addition of an FITC-
labeled secondary antibody (Santa Cruz). Each experiment
was performed with three replicated dishes. Images were
observed under a Leitz microscopy equipped with a fluores-
cence lamp and appropriate filters, and photographed at a
magnification of ×400.
Results
Expression of COX2 in various colon cancer cell lines
First, we determined if COX2 was expressed in HCA7
and HCT116 colon cancer cells using Western blot analysis.
As shown in the Fig. 1, HCA7 cells expressed COX2 protein
intensely whereas HCT116 cells express COX2 protein very
faintly.
Effect of NS398 on viability of HCA7 cells
When HCA7 cells were incubated for 48 h with NS398,
there was no significant decrease in cell viability at
concentrations up to 10 µM. However, viability declined
significantly by 10% at 100 µM (Fig. 2). Therefore, we used
the NS398 concentrations of 1 and 10 µM for the following
experiments.
Expression of proteins of the FasL and TRAIL systems on
colon cancer cell lines, Jurkat and U937 cells
We next evaluated the expression of FasL and TRAIL in
two colon cancer cell lines, HCA7 and HCT116, the former
being COX2 positive and the latter negative. Western
blotting indicates that FASL and TRAIL were expressed
constitutively in both colon cancer cell lines as shown in
Fig. 3. To further assess the localization of those proteins in
the cells, HCA7 and HCT116 were immunostained for FasL
or TRAIL and viewed under a fluorescence microscopy.
Both FasL and TRAIL were detected predominatly as
intense green florescence spots in the intracellular compart-
ment with some faint fluorescence along the cell membrane
(Fig. 4).
Treatment with NS398, a selective inhibitor for COX2,
resulted in a marked reduction of expression of FasL and
Fig. 1. Detection of COX-2 protein in human colonic adeno-
carcinoma cell lines. Colonic adenocarcinoma cells
(HCA7and HCT116) were cultured in DMEM supple-
mented with 10% FCS. When cells became sub-
confluent, cells were lysed as described in Materials and
Methods. COX2 protein was detected in the cell lysates
with Western blotting. Representative photograph of
bands showing COX2 protein (72 kD).
Fig. 2. Effect of increasing concentrations of a COX2 selective
inhibitor NS398 on viability of HCA7 cells. HCA7 cells
were cultured for 48 h in the presence of 0–100 µM
NS398. Subsequently, cell viability was determined using
WST method. *p<0.005 vs 0 µM.Q. Wang et al.
J. Clin. Biochem. Nutr.
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TRAIL in HCA7 cells. In contrast, NS398 did not affect
the expression of FasL and TRAIL in HCT116 cells (Fig. 3,
upper panel).
On the other hand, Jurkat cells, a CTL lineage, expressed
both Fas and DR4. However, U937, a cell line derived from
macrophage, expressed neither Fas nor DR4 (Fig. 3, lower
Fig. 3. Expression of proteins of the FasL and TRAIL systems on colon cancer cell lines, Jurkat and U937 cells. Upper panel: HCA7
and HCT116 (upper panel) , and Jurkat and U937 cells (lower panel) were cultured in the absent or presence of NS398 (10 µM).
After an 18 h of incubation, whole cell lysate was extracted and the expression of apoptosis related proteins (FASL and TRAIL
in HCA7 and HCT116 cells; Fas and DR4 in Jurkat and U937 cells) was examined by Western blotting. Representative
photograph of bands showing FasL (38 kD), TRIAL (38 kD), Fas (48 kD) and DR4 (60 kD).
Fig. 4. Immunostaining analysis for FasL and TRAIL expression in HCA7 and HCT116 cells. After a 48 h of culture, HCA7 and
HCT116 cells were fixed with paraformaldehyde and processed for immunostaining using a first antibody for TRAIL or FASL
followed by visualization with an FITC-labeled secondary goat anti-rabbit antibody as described in Materials and Methods.
Magnification (×400)COX2 Modulates Killing of CTL by Colon Cancer Cells
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panel). NS398 failed to alter the expression of these proteins
in both cells.
Effects of NS398 on the cytotoxic ability of HCA7 and
HCT116 cells against Jurkat cells
The CTL system constitutes a major part of the tumoricidal
machinery of immunity. Therefore inhibition of CTL func-
tions or their survival should favor genesis and growth of
tumor cells. Given this, the cytotoxic ability of colon cancer
cells against Jurkat cells was evaluated in a co-culture
system of colon cancer cells (HCA7 or HCT116) and Jurkat
cells. The results were displayed in Fig. 5. The number of
viable Jurkat cells was diminished by about 25% when cells
were co-cultured (T/E ratio = 10) with naive, non-pretreated
HCA7 cells that were COX2-positive (Fig. 5, left). Under
the same conditions, preincubation of HCA7 cells with
NS398 at 1.0 or 10 µM before co-culture blunted the HCA7
cell-induced cell toxicity on Jurkat cells in a dose-dependent
manner reaching a almost complete loss of cytotoxicity at
10 µM.
Co-culture of Jurkat cells with a COX2-negative colon
cancer cells gave distinct results. As illustrated in Fig. 5
right, co-culture with naïve HCT116 cells resulted in a
decrease of viability of Jurkat cells by 40%. However,
pretreatment with NS398 (1.0 or 10 µM) failed to inhibit
the HCT116-induced Jurkat cell cytotoxicity.
To determine if the Jurkat cell killing by HCA7 was
mediated by FasL or TRAIL, HCA7 cells were incubated
with either a neutralizing antibody for FasL, or TRAIL, or
with both before co-culture with Jurkat cells. As depicted in
Fig. 6, either anti-FasL or anti-TRAIL antibody alone could
suppress the killing of Jurkat cells. Pretreatment of HCA7
cells with both antibodies resulted in a complete inhibition
of Jurkat cell killing (Fig. 6).
Discussion
The results of our study showed that killing of Jurkat cells
occurs when co-cultured with colon cancer cells, HCA7 and
HCT116. This observation agrees with previous reports that
colon cancer cells exploit a machinery to evade immuno-
surveillance through counterattacking tumoricidal CTLs
[29,  33]. NS398, a selective COX2 inhibitor, attenuated
the HCA7-mediated Jurkat cell cytotoxicity. This events
appears likely to be mediated by two molecular systems
for cell death, FasL/Fas and TRAIL/DR4. The view is
supported by the following lines on evidence. First, pretreat-
ment with NS398 reduced expression of FasL and TRAIL
Fig. 5. Effects of NS398 on the cytotoxic ability of HCA7 and HCT116 cells against Jurkat cells. HCA7 and HCT116 cells pretreated
with NS398 (0, 1, or 10 µM) for 18 h and used for co-culture with 3H thymidine labeled Jurkat cells for 18 h. Subsequently,
cells were collected and radioactivity was counted by a scintillation counter. As a control, Jurkat cells were cultured for 18 h
without colon cancer cells. *p<0.001, **p<0.05 vs appropriate control. NS; not significant.
Fig. 6. Effects of nerutralizing antibodies for FASL or/and
TRAIL on the cytotoxic ability of HCA7 and HCT116
cells against Jurkat cells. Conditions as in Fig. 5. HCA7
and HCT116 cells pretreated with either anti-FasL or
anti-TRAIL antibody, or with both (anit-Fas + anti-
TRAIL) for 18 h. After co-culture with Jurkat cells,
cytotoxicity of Jurkat cells was assayed as described in
Fig. 5. *p<0.001 vs control.Q. Wang et al.
J. Clin. Biochem. Nutr.
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on HCA7 cells. Secondly, HCA7-mediated cell killing was
diminished by pretreatment with anti-FasL or anti-TRAIL
neutralizing antibody. It is thus postulated that both of FasL
and TRAIL contribute to the cytotoxicity (Fig. 6).
Although the anti-cancer efficacy of COX2 selective
inhibitors has been reported, most of studies have focused
on the direct effects on tumorigenicity and/or malignant
potentials of colon cancer cells [15–17, 34, 35]. Our results
indicate that COX2 regulates the expression of FasL and
TRAIL on COX2-positive colon cancer cells thereby evoking
a counter-attack against CTLs leading to compromised host
immune responses (Fig. 7). This adds to a new insight into
the role of COX2 in the progression of colon cancer cells
given that numerous numbers of immune cells are infiltrated
in and adjacent to colon tumors [20], an event constituting a
defense mechanism against tumors through damaging tumor
cells. As COX2 is expressed at an early stage of colon
neoplasm [7], the effects of COX2 inhibitors on preventing
the counterattack potentials of tumor cells through reduction
of FasL and TRAIL may explain, at least in part, a mecha-
nism for the chemopreventive effects of COX2 selective
inhibitors.
Several points were left to be elucidated in the future
studies. Among them, it is not clear yet how FasL and/or
TRAIL upregulation in colon cancer cells evokes induction
of apoptosis in CTLs. Beside a notion that membrane-
harboring death molecules exert their effects through
engaging directly with respective receptors on CTLs, there
is a possibility that tumor cells secret FasL and/or TRAIL-
bearing microvesicles thereby inducing CTL apoptosis [36].
The latter mechanism appears intriguing and likely to play a
major role in the HCA7-induced Jurkat cell apoptosis given
that FasL and TRAIL proteins were predominatly localized
in the intracellular vesicular compartments though only a
faint expression of these proteins was observed in HCA7
and HCT116 cells (Fig. 4). Furthermore, the precise
machinery by which COX2 regulates expression of FasL
and TRAIL is also obscure.
In conclusion, the effect of COX2 selective inhibition to
attenuate the counterattack of cancer cells against immune
effector cells is a possible molecular mechanism through
which COX2 inhibitors prevent the growth of adenomatous
polyps or progression of colon cancers.
Abbreviations
COX2, cyclooxygenase 2; TIL, tumor infiltrating lympho-
cyte;  CTL, cytotoxic T lymphocyte; FasL, Fas ligand;
DMEM, Dulbecco’s modified Eagle medium; 3HMT,  3H-
methyl-thymidine; T/E ratio, the ratio of effector cells to
target cells.
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